Injecting Pharmaceutical Skill into Schizophrenia Care

Educational Objectives

After participating in this activity, pharmacists will be able to:

  • Discuss how schizophrenia's propensity to cause internal conflict and subjective distress often leads to nonadherence and use patient centered approaches to improve care
  •  Implement pharmacologic approaches to address suboptimal outcomes for persons with schizophrenia
  •  Identify situations in which oral, long-acting injectable (LAI) antipsychotics, or a combination of both are reasonable choices
  •  Compare available long-acting injectable antipsychotic agents' indications, risks and benefits, pharmacokinetic profiles, dosing, and administration techniques in the pharmacy
  •  Discuss emerging opportunities for pharmacists administer and monitor LAI antipsychotic medication

After participating in this activity pharmacy technicians will be able to:

  • Discuss the association between schizophrenia diagnosis and medication adherence
  • List long-acting injectable drugs used in schizophrenia, and address inventory management issues
  • Recognize when to refer patients to the pharmacist for help with their schizophrenia
  • Determine the best way to help patients engage in a patient assistance program

Session Offered

Release Date: November 15,2019

Expiration Date: November 15,2021

Course Fee

Free

Session Codes

19YC61-ABC36 Pharmacist

19YC61-CBA88 Pharmacy Technician

Accreditation Hours

2.0 hours of CE

Abstract

Schizophrenia is a severe, persistent mental illness that affects 0.3% to 0.7% of the U.S. population. Individuals with schizophrenia often lack insight into their illness and struggle with periods of adequate and inadequate symptom control. Individuals are often stigmatized by a community that is uncomfortable with schizophrenia's symptoms due to fear and misunderstanding. The antipsychotics that have been developed over the last 60 or more years have numerous side effects and require close monitoring. Lack of insight, stigma, and side effects put individuals with schizophrenia at high risk for medication nonadherence, poor clinical outcomes, and costly hospitalizations. More antipsychotics are available in long-acting injectable formulations. These delayed-release formulations allow patients to maintain therapeutic levels of antipsychotics for weeks to
months after an injection. Such properties can help improve medication adherence. In some states, pharmacists can administer LAIAs in community pharmacies and improve patient access to these valuable medications.

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.2 CEU (2 contact hours) for completing the activity, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor on- line system and your participation will be recorded with CPE Monitor within 72 hours of submission

ACPE UAN:
0009-0000-19-061-H01-P
0009-0000-19-061-H01-T

Grant funding: Merck Sharp & Dohme Corp.

Cost: Free

Initial Release Date: November 15, 2019
Expiration Date: November 15, 2021

To obtain CPE credit, visit the UConn Online CE Center

Use your NABP E-profile ID and the session code 19YC61-ABC36 for pharmacists or 19YC61-CBA88 for pharmacy technicians to access the online quiz and evaluation.

First- time users must pre-register in the Online CE Center. Test results will be displayed immediately and your participation will be recorded with CPE Mon- itor within 72 hours of completing the requirements.

For questions concerning the online CPE activities, email joanne.nault@uconn.edu

Faculty:

 

Nathaniel Rickles, PharmD, PhD, BCPP, Associate Clinical Professor

Kristin Waters, PharmD, BCPS, BCPP, Assistant Clinical Professor, University of Connecticut

Faculty Disclosure

The authors have no actual or potential conflicts of interest associated with this article.

Disclosure of Discussions of Off-label and Investigational Drug Use

This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Content

Introduction

Schizophrenia is a chronic, debilitating, serious mental illness (SMI) that affects approximately 0.3 to 0.7% of the global population. Patients with schizophrenia have a significant decline in life expectancy. In a comparison of 220 unique disease conditions, acute schizophrenia was shown to impose the highest degree of disability.1 Schizophrenia’s economic burden is high, with an approximated cost of $155.7 billion in the United States in 2013.2

References

Full List of References

1. Faden J, Citrome L. Resistance is not futile: treatment-refrac-tory schizophrenia - overview, evaluation and treatment. Expert Opin Pharmacother. 2019;20(1):11-24.

2. Cloutier M, Sanon Aigbogun M, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764‐771.

3. Mey A, Fowler JL, Knox K, et al. Review of community pharmacy staff educational needs for supporting mental health consumers and carers. Community Ment Health J. 2014;50(1):59-67.

4. O'Reilly CL, Bell JS, Kelly PJ, Chen TF. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Res Social Adm Pharm. 2015;11(3):e101-e109.

5. Phokeo V, Sproule B, Raman-Wilms L. Community pharmacists’ attitudes toward and professional interactions with users of psychiatric medication. Psychiatr Serv 2004;55:1434–1436.

6. Rickles N, Dube G, McCarter A, Olshan J. Relationship between attitudes toward mental illness and provision of pharmacy services. J Am Pharm Assoc. 2010;50:704–713.

7. Aaltonen SE, Laine NP, Volmer D, et al. Barriers to medication counseling for people with mental disorders: a six country
study. Pharm Pract. 2010;8:122–131.

8. Taylor DM, Velaga S, Werneke U. Reducing the stigma of long acting injectable antipsychotics - current concepts and future developments. Nord J Psychiatry. 2018;72(sup1):S36-S39.

9. Phan SV, VandenBerg AM. Financial impact of a pharmacistmanaged clinic for long-acting injectable antipsychotics. Am J Health Syst Pharm. 2012;69(12):1014-1015.

10. Stroup TS. What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia? J Clin Psychiatry.
2014;75(11):1261-1262.

11. Stilo SA, Murray RM. Non-genetic factors in schizophrenia. Curr Psychiatry Rep. 2019;21(10):100.

12. Hafner H. From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions. Psychiatry J. 2019. Apr 16;2019:9804836. doi: 10.1155/2019/9804836. eCollection 2019.

13. Younas M, Bradley E, Holmes N, Sud D, Maidment ID. Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness. Int J Clin Pharm.2016;38(5):1191-1199.

14. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909.

15. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40:630–639.

16. Valenstein M, Kavanagh J, Lee T, et al. Using a pharmacybased intervention to improve antipsychotic adherence among
patients with serious mental illness. Schizophr Bull. 2011 Jul;37(4):727-736.

17. Dewan MJ. The psychology of schizophrenia: Implications for biological and psychotherapeutic treatments. J Nerv Ment Dis.2016;204(8):564-569.

18. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of secondgeneration antipsychotics versus first-generation antipsychotics.Mol Psychiatry. 2013;18(1):53–66.

19. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43-62.

20. Higashi K, Medic G, Littlewood KG, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol.
2013;3(4):200-18.

21. Morrison AP, Pyle M, Gumley A, Schwannauer M, Turkington D, MacLennan G, Norrie J, et al. Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. Health Technol Assess. 2019;23(7):1-144.

22. Kim J, Ozzoude M, Nakajima S, et al. Insight and medication adherence in schizophrenia: an analysis of the CATIE trial. Neuropharmacology. 2019 May 9:107634. doi: 10.1016/j.neuropharm.2019.05.011. [Epub ahead of print]

23. Jorgensen R, Licht RW, Lysaker PH, Munk-Jorgensen P, Buck KD, Jensen SO, et al. Effects on cognitive and clinical insight with the use of Guided Self-Determination in outpatients with schizophrenia: a randomized open trial. Eur Psychiatry.2015;30(5):655-63.

24. Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017. Drug Alcohol Depend. 2018;191:234-58.

25. Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI.The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophr Res. 2018;194:78-85.

26. Lehman A, Lieberman JA, Dixon LB, McGlashan TH, Miller A, Perkins DO. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry. 2004;161(2):1-56.

27. Hasan A, Falkai P, Wobrock T, et al. Wold Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1. World J Biol Psychiatry.2012;13(14):2-44.

28. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. 2014.

29. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 (Suppl 1): S35–40.

30. Chen YL, Chen KP, Chiu CC, Tai MH, Lung FW. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. BMC Psychiatry. 2018; 18(1):376.

31. Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013 Jul;27(7):545-72.

32. Ogino S, Miyamoto S, Miyake N, Yamaquchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci.2014;68(1):37-49.

33. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf. 2000;22(1):73-81.

34. Patel RS, Mansuri Z, Motiwala F, Saeed H, Jannareddy N, Patel H, et al. A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. Ther Adv Psychopharmacol. 2019;9.

35.Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry.
2019;64(6):388-99.

36. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord.2002;26(1):137-41.

37. Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Muller DJ, Hahn MK. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment. Front Neuerosci. 2018;11:741.

38. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231-41.

39. Siskind D, Friend N, Russell A, et al. CoMET: a protocol for a randomized controlled trial of co-commencement of metformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. BMJ Open. 2018;8(3):e021000.

40. Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032-40.

41. Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychiatric disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatr Res 2016;246:750-755.

42. Park SC, Choi MY, Choi J,et al. Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis. Clin Psychopharm Neuro 2018;16(4):361-375.

43. Kishi T, Oya K, Iwata N. Long-acting antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-analyses of randomized controlled trials. In J Neuropharm 2016;19(9):1-10.

44. Fluphenazine deconate [package insert]. Chestnut Ridge, NY: Par Pharmaceutical; 2016.

45. Haloperidol decanoate [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2019.

46. ABILIFY MAINTENA® (aripiprazole) [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2019.

47. ARISTADA® (aripiprazole lauroxil) [package insert]. Waltham, MA: Alkermes, Inc.; 2019.

48. ZYPREXA RELPREVV (olanzapine) [package insert]. Indianapolis, IN: Lilly USA, LLC; 2018.

49. INVEGA SUSTENNA® (paliperidone palmitate) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2018.

50. INVEGA TRINZA® (paliperidone palmitate) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2018.

51. PERSERIS (risperidone) [package insert]. North Chesterfield, VA: Indivior Inc.; 2018.

52. Risperdal Consta (risperidone) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2019.

53. Ostuzzi G, Bighelli I, So R, Furokawa TA, Barburi C. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res 2017;183:10-21.

54. Zyprexa Relprevv Program. Available at https://www.zyprexarelprevvprogram.com/PDF/Lilly%20Zyprex
a%20Relprevv%20Folder%20Booklet.pdf. Accessed October 23, 2019.

55. Shah A, Lin X, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018;35(11):1994-2014.

56. National Community Pharmacists Association. Administration of Long-Acting Anti-psychotic Injectable Medications. Available at https://www.ncpanet.org/innovation-center/diversifiedrevenue-opportunities/administration-of-long-acting-injectable.Accessed October 10, 2019